Was it $5B Zimbabwe dollaz or falaks please clarify number of $000,000,000 they delivered you in 5 years?
This is all dubai sand castle staff ..Please ask someone to pinch you if you are dreaming mr. waked

PSPW 3Power Group enchalla river of broken dreams and promises may finally run out of countless lies and deception stories to tell unsuspecting investors.
Here is 3 red flags and signs of fraud, Hope even strongest believers wake up and admit their losses:
#1 3Power Group is in default and owes millions + interest to Swiss CRG Group international investor
#2 Public company stopped reporting and late filling financial reports. Hiding fraud and audit firm will not issue opinion or can’t afford to pay auditors.
#3 credibility of 3Power managmentvteam is $0 as any company in default is $0. Net tengible sssets is $0
It will cost more money to close the door then liquidating 3 couches and five pens they own
Conclusion: anyone holding this dead smelly camel and hoping it runs again is dilusional dreamer who denies the inevitable total loss on investment.

Good entree point. This is nobrainer trading close to cash value and big institutional guys in it See bio CEO:

Mr. Douglas Lindsay Wu, MBA, has been the Chief Executive Officer of Africa Hydrocarbons Inc since June 1, 2017. Mr. Wu has been Executive Chairman and Interim Chief Executive Officer of Greatbanks Resources Ltd. since April 25, 2017. Mr. Wu serves as the Chief Financial Officer of NOOR Group Limited. Mr. Wu is a Principal of Maxwell Partners. He is Managing Partner of Whitwell Partners and Senior Advisor to a family office. Mr. Wu co-founded G2 Natural Resources, LLC, an affiliate of G2 Investment Group and served as its Chief Executive Officer since 1997. For more than 30 years he has been a private equity investor with experience in hedge fund and private equity investing in the natural resource sector and a variety of industries. Mr. Wu began his career at the Thomas H. Lee Company. Mr. Wu has helped build businesses on a venture capital basis and assisted in financing them through multiple rounds with leading institutional investors. He served as Chief Financial Officer of Seafield Resources Ltd. since July 2011. From July 1998 to December 1998, Mr. Wu served as a Principal of Libra Advisor LLC. From 1996 to 1998, he served as Managing Director of Private Equity Investment at Rothschild Emerging Markets LLC / Croesus Capital Management Corporation. He has been Director of Greatbanks Resources Ltd. since April 20, 2017. He has been Director of Africa Hydrocarbons Inc. since June 1, 2017. He served as a Director at Bexil Corp. from 1997 to July 2015 and Seafield Resources Ltd. from May 4, 2011 to May 29, 2012. He served as a Director of Tuxis Corp. since 2002. He is a graduate of Harvard College and Harvard Business School and is Industrial Sector Leader for Harvard Business School Alumni Angels of New York.

http://blockchaink2.com
15,900,000 issues with 2000 shareholders of record see fillings on
OTCQB under BIDCF cool symbol something is up here

I was buying BITK in Canada as they trade near cash per share value. Financing was done at $1.25 less then 3 month ago. Strong management team with CEO ex hedge fund guy running yye show.
Now that the stock is listed under BIDCF will pick more thinly traded shares. Should double on any buying interest found this article from Friday

http://www.investorideas.com/news/2018/blockchain/08031TSXVBITK.asp

BlockchainK2, Corp. TSXV: BITK extremely oversold stock price trades under KNPRF US pink sheets

http://blockchaink2.com trades on TSXV symbol BITK company is no longer oil and gas issuer and changed to crypto Blockchain Focus

I bought some today trading at 40% discount to most recent funding round at $1,25 per share see news BITK.TSXV BlockchainK2 Corp solid Managment Team on their website

New name and new trading symbol BITK.V BlockchainK2, Corp company raised more then $4,000,000 at $1.25 per share stock started to trade last night

New management team stepped in renamed Africa Africa Hydrocurbons oil and gas co into BlockchainK2 corp
Ticker: BITK
Here is news and info from sedan fillings

BlockchainK2 Corp. Begins Trading on TSX Venture Exchange
V.BITK
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- BlockchainK2 Corp. (formerly Africa Hydrocarbons Inc.) (TSX.V:BITK) (the “Company”) is pleased to announce that it will today begin trading on the TSX Venture Exchange under the stock symbol “BITK”.

As per the Company’s May 25, 2018 press release, it has recently completed a “Change of Business” transaction (the “COB Transaction”) and now operates as a blockchain technology company, with its initial business being cryptocurrency mining. The Company will continue to update the market as it orders additional cryptocurrency mining equipment and develops its cryptocurrency mining facility.

Additional Information

Additional information about the Company and the COB Transaction is available on SEDAR at www.sedar.com under the Company’s profile. The summary of the COB Transaction set out above is qualified in its entirety by reference to the description of the COB Transaction in the Filing Statement. At this time there are 15,901,625 common shares of the Company issued and outstanding.

ON BEHALF OF THE BOARD OF
BLOCKCHAINK2 CORP.

Douglas Wu
CEO and Director

For further information, please telephone: (604) 283-1722.


Read more at http://www.stockhouse.com/news/press-releases/2018/05/31/blockchaink2-corp-begins-trading-on-tsx-venture-exchange#UzAyEMA7KTGLGuVm.99


http://www.stockhouse.com/companies/quote?symbol=v.bitk



http://blockchaink2.com

Douglas Wu - Mr. Wu has over twenty five years experience in hedge fund and private equity investing in a variety of industries both in the US and internationally. He has helped build businesses on a venture capital basis and assisted in financing them through multiple rounds with leading institutional investors. Among the investments he has worked on are: African uranium company (sold to Areva for $2.5 billion, less than 30 months from the date the company was founded, resulting in a 54x return to initial institutional investors); midstream energy infrastructure company (roll-up of liquid terminal assets) in partnership with ex-Kinder Morgan management team sold to a $9 billion energy private equity firm; insurance services division of AIG (acquisition and sale at over 30x initial equity investment); tobacco company in Africa and Middle East (pre-ipo round led by Goldman Sachs and leading emerging market hedge funds); early investments in independent energy service and oil and gas companies in Canada that subsequently became large public companies including Trican, Bonavista, Compton; roll-up of health care services businesses (acquisitions and sale to Bain Capital); manufacturer of specialty paper products acquired from Dyson Kissner Moran interests (acquisition and recapitalizations that returned over 80x initial equity investment); acquisition of manufacturer of specialty steel products; management buyout of leading mail order office supply company; management buyout of leading investment advisory firm.

Mr. Wu is Senior Advisor to a family office and a director of an acquisitive holding company in the financial services sector. He was formerly Managing Director of Rothschild Emerging Markets LLC/ Croesus Capital Management, a hedge fund group affiliated with Rothschild, Inc. Mr. Wu began his career at the Thomas H. Lee Company, a private equity firm. He is a graduate of Harvard College and Harvard Business School.


Mr. Sergei Stetsenko is the Founder of CRG Finance AG and has been its Chief Executive Officer since August 2009. During his career of 20 years, he has raised over $250 million for companies which have been involved in various business segments. He was the Founder of Triangle Petroleum Corporation and served as its Chief Executive Officer since 2005. He served as the Principal Executive Officer and President of Triangle Petroleum Corp. from December 11, 2003 to May 12, 2005. Mr. Stetsenko served as the Treasurer of Triangle Petroleum Corp. since December 11, 2003. He served as the Principal Financial Officer and Principal Accounting Officer of Triangle Petroleum Corp. from December 11, 2003 to October 2005. Mr. Stetsenko served as a Secretary of SNRG Corporation and Ancona Mining Corporation. In June 2015 he founded Vynleads Inc. Mr. Stetsenko served as the Secretary of VisualMED Clinical Solutions Corp. from September 7, 1999 to October 2004. He served as a Secretary of Xinhua China Ltd. since February 14, 1999. Mr. Stetsenko served as the Operations Manager of Exploration at Callinan Royalties Corporation from October 1996 to June 2001. From December 1994 to June 1996, he served as the Operations Manager of Booker Gold Explorations Ltd. Mr. Stetsenko's responsibilities included overseeing and implementation of exploration programs and a member of the Hearne Hill copper deposit discovery team. From September 1999 to February 2002, he served as a Secretary of Palal Mining Corp. He has been a Director of Greatbanks Resources Ltd. since April 20, 2017. He serves as a Director of Africa Hydrocarbons Inc. Mr. Stetsenko served as a Director of Triangle Petroleum Corp. from December 11, 2003 to July 29, 2005. He served as a Director of Xinhua China Ltd. since February 14, 1999 and VisualMED Clinical Solutions Corp. from September 7, 1999 to October 2004. Mr. Stetsenko served as a Director of Ancona Mining Corporation and SNRG Corporation. He is a financier and specialist with 20 years of experience in private equity and venture capital investments.

Dr. Bob McElrath is Vice President of Block Chain System Architecture at Fidelity Investments, a leading financial institution. He was previously a serial CTO, Chief Scientist and Software Developer for blockchain technology companies including SolidX (cryptographic keys for identity) and Ribbit Rewards (cryptocurrencies for airline rewards programs). He is an experienced cryptocurrency developer and team leader with experience in bitcoin and ethereum. He was formerly Senior Software Developer at Bloomberg and has a PhD in theoretical particle physics from the University of Wisconsin. Dr. McElrath did his post doctorate work at the University of California and at CERN and has over 32 publications.
Michael Maloney is a Managing Director at Galaxy Digital, a leading digital currency/ blockchain merchant bank, where he leads the Advisory Services practice. He has extensive technology advisory, architecture design, and blockchain experience, and has been active in development within the space since 2011. He has developed numerous blockchain applications for clients across a variety of industries, including; digital goods and games trading, supply chain management, anti-money laundering and KYC regulatory compliance, and language processing and machine learning marketplaces. Formerly, Michael led Distributed Ledger technology development at EY, and worked with an international team to introduce and provide solutions to global companies. He has additional experience across a number of regulatory spaces, including government and 3rd party oversight agencies. Michael has a strong background in statistical analysis and technology implementation, and has performed a variety of services ranging from developing custom transaction monitoring solutions, advanced data reporting and solution / vendor selection, to realized GPS and event-triggered mobile applications. Outside of work, Michael develops blockchain and IOT integrated hardware for personal use.

Geoff Hampson brings over 30 years as an investor, acquirer, senior executive and director of start-up, turnaround and high growth companies. Geoff has completed transactions in the industrial manufacturing, real estate, internet infrastructure, mining, and oil & gas sectors where he has been able to build strong teams to lead businesses into sector leading positions. Geoff built up a data center/ cloud business, Peer 1 Network, sold to Cogeco for $565 million. Geoff is an investor and Director of many small and mid-sized companies throughout Canada, Europe and the USA. Geoff currently serves as the Chairman of the Board and CEO of Fibrox Technology Ltd., a North American leader in the production of mineral fiber. He also serves as the Chairman of the Board and CEO of Para Resources Inc., a publicly-listed company on the Exchange focusing on North and South American gold properties. Geoff served as a member of the University of British Columbia’s International Advisory Board. He is active in local and international associations and charities. Geoff has lived and worked in both Canada and the USA.
John Lema is a serial technology CEO and CTO. He is currently CEO of Elevate, a venture backed real estate SAS company partnered with several of the largest commercial real estate firms. He is formerly CTO of Convene and CEO/ founder of ScrollMotion, a leading B2B SAS platform that was the largest supplier of apps to iTunes. He led sales teams servicing leading clients including GE, Exxon and Toyota. He was E&Y Entrepreneur of the Year Finalist in 2012 and is a graduate of Carnegie Mellon.

Tom St. Laurent is Technical Director of Blockchain Technologies Corp, a leading blockchain incubator and development firm founded in 2010. Tom has been a bitcoin fanatic for over six years. Over the past decade, he has developed social gaming software, virtual merchandising engines at scale, architecture for promotional frameworks for media conglomerates. Tom led development at the Zap Project, a blockchain platform for curating reliable information authorities (Oracles) that deliver real world data to smart contracts. Before joining Zap, Tom led engineering at Gimli.io, an eSports betting platform built on the Ethereum blockchain, allowing users to wager on their favorite streams. Tom has a BS in Physics from Manhattan College.
Joseph Fiscella is Senior Blockchain Developer at Galaxy Investment Partners, founded by Michael Novogratz, a former co-founder of Fortress Investment Group and a former partner at Goldman Sachs. Joe is a Blockchain Developer and an early adopter of digital currencies. He is the lead developer of the Florincoin project and co-founder of Alexandria, the first fully peer-to-peer decentralized video streaming application. Joseph is a long-time member of the bitcoin NYC community and has worked with numerous NYC blockchain and bitcoin startups, including Blocktech, SolidX Partners, and Blockchain of Things. Joe has a BS in Computer Science from Manhattan College.

Wayne Nemeth is a technology company CEO, advisor and investor. He was formerly CEO/ COO of
T+ink, a venture backed electronic ink company connecting retail inventory to Internet of Things. He was founder of Pelap Group, an advisory and investment firm focused on SAS and data analytics. For 10 years, Wayne was a Partner at Sprout Group, a $3 bn venture capital firm owned by DLJ/ Credit Suisse. Board roles include: Calix, DynamicOps (acquired by VM Ware), Internet Phonics (acquired by Ciena) and Lefthand Networks (acquired by HP). He is a graduate of University of Pennsylvania and The Wharton School.

BlockchainK2 Corp. Begins Trading on TSX Venture Exchange
V.BITK
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- BlockchainK2 Corp. (formerly Africa Hydrocarbons Inc.) (TSX.V:BITK) (the “Company”) is pleased to announce that it will today begin trading on the TSX Venture Exchange under the stock symbol “BITK”.

As per the Company’s May 25, 2018 press release, it has recently completed a “Change of Business” transaction (the “COB Transaction”) and now operates as a blockchain technology company, with its initial business being cryptocurrency mining. The Company will continue to update the market as it orders additional cryptocurrency mining equipment and develops its cryptocurrency mining facility.

Additional Information

Additional information about the Company and the COB Transaction is available on SEDAR at www.sedar.com under the Company’s profile. The summary of the COB Transaction set out above is qualified in its entirety by reference to the description of the COB Transaction in the Filing Statement. At this time there are 15,901,625 common shares of the Company issued and outstanding.

ON BEHALF OF THE BOARD OF
BLOCKCHAINK2 CORP.

Douglas Wu
CEO and Director

For further information, please telephone: (604) 283-1722.


Read more at http://www.stockhouse.com/news/press-releases/2018/05/31/blockchaink2-corp-begins-trading-on-tsx-venture-exchange#UzAyEMA7KTGLGuVm.99


http://www.stockhouse.com/companies/quote?symbol=v.bitk



http://blockchaink2.com

Douglas Wu - Mr. Wu has over twenty five years experience in hedge fund and private equity investing in a variety of industries both in the US and internationally. He has helped build businesses on a venture capital basis and assisted in financing them through multiple rounds with leading institutional investors. Among the investments he has worked on are: African uranium company (sold to Areva for $2.5 billion, less than 30 months from the date the company was founded, resulting in a 54x return to initial institutional investors); midstream energy infrastructure company (roll-up of liquid terminal assets) in partnership with ex-Kinder Morgan management team sold to a $9 billion energy private equity firm; insurance services division of AIG (acquisition and sale at over 30x initial equity investment); tobacco company in Africa and Middle East (pre-ipo round led by Goldman Sachs and leading emerging market hedge funds); early investments in independent energy service and oil and gas companies in Canada that subsequently became large public companies including Trican, Bonavista, Compton; roll-up of health care services businesses (acquisitions and sale to Bain Capital); manufacturer of specialty paper products acquired from Dyson Kissner Moran interests (acquisition and recapitalizations that returned over 80x initial equity investment); acquisition of manufacturer of specialty steel products; management buyout of leading mail order office supply company; management buyout of leading investment advisory firm.

Mr. Wu is Senior Advisor to a family office and a director of an acquisitive holding company in the financial services sector. He was formerly Managing Director of Rothschild Emerging Markets LLC/ Croesus Capital Management, a hedge fund group affiliated with Rothschild, Inc. Mr. Wu began his career at the Thomas H. Lee Company, a private equity firm. He is a graduate of Harvard College and Harvard Business School.


Mr. Sergei Stetsenko is the Founder of CRG Finance AG and has been its Chief Executive Officer since August 2009. During his career of 20 years, he has raised over $250 million for companies which have been involved in various business segments. He was the Founder of Triangle Petroleum Corporation and served as its Chief Executive Officer since 2005. He served as the Principal Executive Officer and President of Triangle Petroleum Corp. from December 11, 2003 to May 12, 2005. Mr. Stetsenko served as the Treasurer of Triangle Petroleum Corp. since December 11, 2003. He served as the Principal Financial Officer and Principal Accounting Officer of Triangle Petroleum Corp. from December 11, 2003 to October 2005. Mr. Stetsenko served as a Secretary of SNRG Corporation and Ancona Mining Corporation. In June 2015 he founded Vynleads Inc. Mr. Stetsenko served as the Secretary of VisualMED Clinical Solutions Corp. from September 7, 1999 to October 2004. He served as a Secretary of Xinhua China Ltd. since February 14, 1999. Mr. Stetsenko served as the Operations Manager of Exploration at Callinan Royalties Corporation from October 1996 to June 2001. From December 1994 to June 1996, he served as the Operations Manager of Booker Gold Explorations Ltd. Mr. Stetsenko's responsibilities included overseeing and implementation of exploration programs and a member of the Hearne Hill copper deposit discovery team. From September 1999 to February 2002, he served as a Secretary of Palal Mining Corp. He has been a Director of Greatbanks Resources Ltd. since April 20, 2017. He serves as a Director of Africa Hydrocarbons Inc. Mr. Stetsenko served as a Director of Triangle Petroleum Corp. from December 11, 2003 to July 29, 2005. He served as a Director of Xinhua China Ltd. since February 14, 1999 and VisualMED Clinical Solutions Corp. from September 7, 1999 to October 2004. Mr. Stetsenko served as a Director of Ancona Mining Corporation and SNRG Corporation. He is a financier and specialist with 20 years of experience in private equity and venture capital investments.

Dr. Bob McElrath is Vice President of Block Chain System Architecture at Fidelity Investments, a leading financial institution. He was previously a serial CTO, Chief Scientist and Software Developer for blockchain technology companies including SolidX (cryptographic keys for identity) and Ribbit Rewards (cryptocurrencies for airline rewards programs). He is an experienced cryptocurrency developer and team leader with experience in bitcoin and ethereum. He was formerly Senior Software Developer at Bloomberg and has a PhD in theoretical particle physics from the University of Wisconsin. Dr. McElrath did his post doctorate work at the University of California and at CERN and has over 32 publications.
Michael Maloney is a Managing Director at Galaxy Digital, a leading digital currency/ blockchain merchant bank, where he leads the Advisory Services practice. He has extensive technology advisory, architecture design, and blockchain experience, and has been active in development within the space since 2011. He has developed numerous blockchain applications for clients across a variety of industries, including; digital goods and games trading, supply chain management, anti-money laundering and KYC regulatory compliance, and language processing and machine learning marketplaces. Formerly, Michael led Distributed Ledger technology development at EY, and worked with an international team to introduce and provide solutions to global companies. He has additional experience across a number of regulatory spaces, including government and 3rd party oversight agencies. Michael has a strong background in statistical analysis and technology implementation, and has performed a variety of services ranging from developing custom transaction monitoring solutions, advanced data reporting and solution / vendor selection, to realized GPS and event-triggered mobile applications. Outside of work, Michael develops blockchain and IOT integrated hardware for personal use.

Geoff Hampson brings over 30 years as an investor, acquirer, senior executive and director of start-up, turnaround and high growth companies. Geoff has completed transactions in the industrial manufacturing, real estate, internet infrastructure, mining, and oil & gas sectors where he has been able to build strong teams to lead businesses into sector leading positions. Geoff built up a data center/ cloud business, Peer 1 Network, sold to Cogeco for $565 million. Geoff is an investor and Director of many small and mid-sized companies throughout Canada, Europe and the USA. Geoff currently serves as the Chairman of the Board and CEO of Fibrox Technology Ltd., a North American leader in the production of mineral fiber. He also serves as the Chairman of the Board and CEO of Para Resources Inc., a publicly-listed company on the Exchange focusing on North and South American gold properties. Geoff served as a member of the University of British Columbia’s International Advisory Board. He is active in local and international associations and charities. Geoff has lived and worked in both Canada and the USA.
John Lema is a serial technology CEO and CTO. He is currently CEO of Elevate, a venture backed real estate SAS company partnered with several of the largest commercial real estate firms. He is formerly CTO of Convene and CEO/ founder of ScrollMotion, a leading B2B SAS platform that was the largest supplier of apps to iTunes. He led sales teams servicing leading clients including GE, Exxon and Toyota. He was E&Y Entrepreneur of the Year Finalist in 2012 and is a graduate of Carnegie Mellon.

Tom St. Laurent is Technical Director of Blockchain Technologies Corp, a leading blockchain incubator and development firm founded in 2010. Tom has been a bitcoin fanatic for over six years. Over the past decade, he has developed social gaming software, virtual merchandising engines at scale, architecture for promotional frameworks for media conglomerates. Tom led development at the Zap Project, a blockchain platform for curating reliable information authorities (Oracles) that deliver real world data to smart contracts. Before joining Zap, Tom led engineering at Gimli.io, an eSports betting platform built on the Ethereum blockchain, allowing users to wager on their favorite streams. Tom has a BS in Physics from Manhattan College.
Joseph Fiscella is Senior Blockchain Developer at Galaxy Investment Partners, founded by Michael Novogratz, a former co-founder of Fortress Investment Group and a former partner at Goldman Sachs. Joe is a Blockchain Developer and an early adopter of digital currencies. He is the lead developer of the Florincoin project and co-founder of Alexandria, the first fully peer-to-peer decentralized video streaming application. Joseph is a long-time member of the bitcoin NYC community and has worked with numerous NYC blockchain and bitcoin startups, including Blocktech, SolidX Partners, and Blockchain of Things. Joe has a BS in Computer Science from Manhattan College.

Wayne Nemeth is a technology company CEO, advisor and investor. He was formerly CEO/ COO of
T+ink, a venture backed electronic ink company connecting retail inventory to Internet of Things. He was founder of Pelap Group, an advisory and investment firm focused on SAS and data analytics. For 10 years, Wayne was a Partner at Sprout Group, a $3 bn venture capital firm owned by DLJ/ Credit Suisse. Board roles include: Calix, DynamicOps (acquired by VM Ware), Internet Phonics (acquired by Ciena) and Lefthand Networks (acquired by HP). He is a graduate of University of Pennsylvania and The Wharton School.

BlockchainK2 Corp. Begins Trading on TSX Venture Exchange
V.BITK
VANCOUVER, British Columbia, May 31, 2018 (GLOBE NEWSWIRE) -- BlockchainK2 Corp. (formerly Africa Hydrocarbons Inc.) (TSX.V:BITK) (the “Company”) is pleased to announce that it will today begin trading on the TSX Venture Exchange under the stock symbol “BITK”.

As per the Company’s May 25, 2018 press release, it has recently completed a “Change of Business” transaction (the “COB Transaction”) and now operates as a blockchain technology company, with its initial business being cryptocurrency mining. The Company will continue to update the market as it orders additional cryptocurrency mining equipment and develops its cryptocurrency mining facility.

Additional Information

Additional information about the Company and the COB Transaction is available on SEDAR at www.sedar.com under the Company’s profile. The summary of the COB Transaction set out above is qualified in its entirety by reference to the description of the COB Transaction in the Filing Statement. At this time there are 15,901,625 common shares of the Company issued and outstanding.

ON BEHALF OF THE BOARD OF
BLOCKCHAINK2 CORP.

Douglas Wu
CEO and Director

For further information, please telephone: (604) 283-1722.


Read more at http://www.stockhouse.com/news/press-releases/2018/05/31/blockchaink2-corp-begins-trading-on-tsx-venture-exchange#UzAyEMA7KTGLGuVm.99


http://www.stockhouse.com/companies/quote?symbol=v.bitk



http://blockchaink2.com

Douglas Wu - Mr. Wu has over twenty five years experience in hedge fund and private equity investing in a variety of industries both in the US and internationally. He has helped build businesses on a venture capital basis and assisted in financing them through multiple rounds with leading institutional investors. Among the investments he has worked on are: African uranium company (sold to Areva for $2.5 billion, less than 30 months from the date the company was founded, resulting in a 54x return to initial institutional investors); midstream energy infrastructure company (roll-up of liquid terminal assets) in partnership with ex-Kinder Morgan management team sold to a $9 billion energy private equity firm; insurance services division of AIG (acquisition and sale at over 30x initial equity investment); tobacco company in Africa and Middle East (pre-ipo round led by Goldman Sachs and leading emerging market hedge funds); early investments in independent energy service and oil and gas companies in Canada that subsequently became large public companies including Trican, Bonavista, Compton; roll-up of health care services businesses (acquisitions and sale to Bain Capital); manufacturer of specialty paper products acquired from Dyson Kissner Moran interests (acquisition and recapitalizations that returned over 80x initial equity investment); acquisition of manufacturer of specialty steel products; management buyout of leading mail order office supply company; management buyout of leading investment advisory firm.

Mr. Wu is Senior Advisor to a family office and a director of an acquisitive holding company in the financial services sector. He was formerly Managing Director of Rothschild Emerging Markets LLC/ Croesus Capital Management, a hedge fund group affiliated with Rothschild, Inc. Mr. Wu began his career at the Thomas H. Lee Company, a private equity firm. He is a graduate of Harvard College and Harvard Business School.


Mr. Sergei Stetsenko is the Founder of CRG Finance AG and has been its Chief Executive Officer since August 2009. During his career of 20 years, he has raised over $250 million for companies which have been involved in various business segments. He was the Founder of Triangle Petroleum Corporation and served as its Chief Executive Officer since 2005. He served as the Principal Executive Officer and President of Triangle Petroleum Corp. from December 11, 2003 to May 12, 2005. Mr. Stetsenko served as the Treasurer of Triangle Petroleum Corp. since December 11, 2003. He served as the Principal Financial Officer and Principal Accounting Officer of Triangle Petroleum Corp. from December 11, 2003 to October 2005. Mr. Stetsenko served as a Secretary of SNRG Corporation and Ancona Mining Corporation. In June 2015 he founded Vynleads Inc. Mr. Stetsenko served as the Secretary of VisualMED Clinical Solutions Corp. from September 7, 1999 to October 2004. He served as a Secretary of Xinhua China Ltd. since February 14, 1999. Mr. Stetsenko served as the Operations Manager of Exploration at Callinan Royalties Corporation from October 1996 to June 2001. From December 1994 to June 1996, he served as the Operations Manager of Booker Gold Explorations Ltd. Mr. Stetsenko's responsibilities included overseeing and implementation of exploration programs and a member of the Hearne Hill copper deposit discovery team. From September 1999 to February 2002, he served as a Secretary of Palal Mining Corp. He has been a Director of Greatbanks Resources Ltd. since April 20, 2017. He serves as a Director of Africa Hydrocarbons Inc. Mr. Stetsenko served as a Director of Triangle Petroleum Corp. from December 11, 2003 to July 29, 2005. He served as a Director of Xinhua China Ltd. since February 14, 1999 and VisualMED Clinical Solutions Corp. from September 7, 1999 to October 2004. Mr. Stetsenko served as a Director of Ancona Mining Corporation and SNRG Corporation. He is a financier and specialist with 20 years of experience in private equity and venture capital investments.

Dr. Bob McElrath is Vice President of Block Chain System Architecture at Fidelity Investments, a leading financial institution. He was previously a serial CTO, Chief Scientist and Software Developer for blockchain technology companies including SolidX (cryptographic keys for identity) and Ribbit Rewards (cryptocurrencies for airline rewards programs). He is an experienced cryptocurrency developer and team leader with experience in bitcoin and ethereum. He was formerly Senior Software Developer at Bloomberg and has a PhD in theoretical particle physics from the University of Wisconsin. Dr. McElrath did his post doctorate work at the University of California and at CERN and has over 32 publications.
Michael Maloney is a Managing Director at Galaxy Digital, a leading digital currency/ blockchain merchant bank, where he leads the Advisory Services practice. He has extensive technology advisory, architecture design, and blockchain experience, and has been active in development within the space since 2011. He has developed numerous blockchain applications for clients across a variety of industries, including; digital goods and games trading, supply chain management, anti-money laundering and KYC regulatory compliance, and language processing and machine learning marketplaces. Formerly, Michael led Distributed Ledger technology development at EY, and worked with an international team to introduce and provide solutions to global companies. He has additional experience across a number of regulatory spaces, including government and 3rd party oversight agencies. Michael has a strong background in statistical analysis and technology implementation, and has performed a variety of services ranging from developing custom transaction monitoring solutions, advanced data reporting and solution / vendor selection, to realized GPS and event-triggered mobile applications. Outside of work, Michael develops blockchain and IOT integrated hardware for personal use.

Geoff Hampson brings over 30 years as an investor, acquirer, senior executive and director of start-up, turnaround and high growth companies. Geoff has completed transactions in the industrial manufacturing, real estate, internet infrastructure, mining, and oil & gas sectors where he has been able to build strong teams to lead businesses into sector leading positions. Geoff built up a data center/ cloud business, Peer 1 Network, sold to Cogeco for $565 million. Geoff is an investor and Director of many small and mid-sized companies throughout Canada, Europe and the USA. Geoff currently serves as the Chairman of the Board and CEO of Fibrox Technology Ltd., a North American leader in the production of mineral fiber. He also serves as the Chairman of the Board and CEO of Para Resources Inc., a publicly-listed company on the Exchange focusing on North and South American gold properties. Geoff served as a member of the University of British Columbia’s International Advisory Board. He is active in local and international associations and charities. Geoff has lived and worked in both Canada and the USA.
John Lema is a serial technology CEO and CTO. He is currently CEO of Elevate, a venture backed real estate SAS company partnered with several of the largest commercial real estate firms. He is formerly CTO of Convene and CEO/ founder of ScrollMotion, a leading B2B SAS platform that was the largest supplier of apps to iTunes. He led sales teams servicing leading clients including GE, Exxon and Toyota. He was E&Y Entrepreneur of the Year Finalist in 2012 and is a graduate of Carnegie Mellon.

Tom St. Laurent is Technical Director of Blockchain Technologies Corp, a leading blockchain incubator and development firm founded in 2010. Tom has been a bitcoin fanatic for over six years. Over the past decade, he has developed social gaming software, virtual merchandising engines at scale, architecture for promotional frameworks for media conglomerates. Tom led development at the Zap Project, a blockchain platform for curating reliable information authorities (Oracles) that deliver real world data to smart contracts. Before joining Zap, Tom led engineering at Gimli.io, an eSports betting platform built on the Ethereum blockchain, allowing users to wager on their favorite streams. Tom has a BS in Physics from Manhattan College.
Joseph Fiscella is Senior Blockchain Developer at Galaxy Investment Partners, founded by Michael Novogratz, a former co-founder of Fortress Investment Group and a former partner at Goldman Sachs. Joe is a Blockchain Developer and an early adopter of digital currencies. He is the lead developer of the Florincoin project and co-founder of Alexandria, the first fully peer-to-peer decentralized video streaming application. Joseph is a long-time member of the bitcoin NYC community and has worked with numerous NYC blockchain and bitcoin startups, including Blocktech, SolidX Partners, and Blockchain of Things. Joe has a BS in Computer Science from Manhattan College.

Wayne Nemeth is a technology company CEO, advisor and investor. He was formerly CEO/ COO of
T+ink, a venture backed electronic ink company connecting retail inventory to Internet of Things. He was founder of Pelap Group, an advisory and investment firm focused on SAS and data analytics. For 10 years, Wayne was a Partner at Sprout Group, a $3 bn venture capital firm owned by DLJ/ Credit Suisse. Board roles include: Calix, DynamicOps (acquired by VM Ware), Internet Phonics (acquired by Ciena) and Lefthand Networks (acquired by HP). He is a graduate of University of Pennsylvania and The Wharton School.

Current audit shows $0 assets or $500 cash. Please let as know how much money they have in the bank? Proof of bank account? Scourging to latest audit PSPW stock is not worth the paper it’s printed on.
This is old pump&dump gig done by bunch of charlatans and shady promoters. Been saying this for years.

PSPW is company in default?

Did anyone care to check if they have any money or even bank account? All we see is blah blah blah for years and no substance. It would be helpful if anyone on board pointed me links with proof to any assets? Thank you in advance.

Right. I alerted all about lies and deception that was not innocent in nature to begin with. Group of promoters pumped and dumped shares while ommiting try facts about 3Power PSPW. Not going anywhere but down and here is reason: insiders are bk and their company in default with millions owed to creditors

PSPW was ordered to pay $1,081,586 to CRG Finance AG by AAA
3 Power Energy Group, Inc. ordered to pay $1,081,586 to CRG Finance AG as Final Award in AAA Arbitration in New York, United States of America http://www.scribd.com/doc/215888558/3-Power-Energy-Group-Inc-PSPW-ordered-to-pay-1-081-586-to-CRG-Finance-AG-as-Final-Award-in-AAA-Arbitration-in-New-York-United-States-of-America

Read more at http://www.stockhouse.com/companies/bullboard#ZVSGre4vTBYC0gYI.99

Please be objective and don’t omit true fact and main reason stock underperformed all this years. 3PowerGroup
PSPW is in default and will be put in eventual liquidation in USA and WorldWide see Court order awarded millions to creditor with 15% interest for life:

http://www.scribd.com/doc/215888558/3-Power-Energy-Group-Inc-PSPW-ordered-to-pay-1-081-586-to-CRG-Finance-AG-as-Final-Award-in-AAA-Arbitration-in-New-York-United-States-of-America

Sernova Receives US FDA IND Allowance to Initiate a US Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes
Source: Sernova Corp December 11, 2017, 6:00 a.m. EDT

LONDON, ONTARIO – (Globe Newswire – Monday December 11, 2017) – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing regenerative medicine technologies for the long-term treatment of diseases including diabetes and hemophilia, is pleased to announce it has received US Food and Drug Administration (FDA) notice of allowance for its IND for a new human clinical trial with the Cell Pouch System (TM) (CPS) in the United States. The Company will host a conference call for shareholders with Dr. Philip Toleikis, President and CEO on Monday, December 11th at 10:00am Eastern Standard Time to discuss the trial.

Sernova plans to initiate the new clinical trial under this US IND to investigate the Cell Pouch for treatment of type 1 diabetes (T1D) in individuals with hypoglycemia unawareness. The trial is a Phase I/II prospective single arm study of islets transplanted into the subcutaneously implanted Cell Pouch. The primary objective of the study is to demonstrate safety and tolerability of islet transplantation into the Cell Pouch and the secondary objective is to assess efficacy through a series of defined measures.

JDRF has previously committed to provide Sernova up to $2.45 million USD to support the clinical trial.

“Hypoglycemia unawareness is a serious consequence of type 1 diabetes,” said Derek Rapp, President & CEO, JDRF International. “We are excited to see progress in this and other potentially life-saving JDRF-funded research, which could help prevent people with hypoglycemia unawareness from experiencing dangerous lows, as we strive to achieve our vision of a world without T1D.”

“We are extremely enthusiastic about the promise of Sernova’s regenerative medicine platform to provide a new therapeutic option for diabetes patients with hypoglycemia unawareness. We believe Sernova’s multiple advancing cell based therapies have the potential to deliver significant improvement in the quality of life of patients suffering from diabetes and other debilitating diseases,” said Dr. Philip Toleikis, Sernova’s president & CEO.

About the Trial

The study is a Phase I/II single site, single arm, Company sponsored trial. Following approval by the Institutional Review Board, patients with hypoglycemia unawareness will be enrolled into the study under informed consent. Patients will then be implanted with the Cell Pouch including sentinel devices. Following vascularized tissue development, a dose of purified islets under strict release criteria will be transplanted into the Cell Pouch and patients followed for safety and efficacy measures for approximately six months. At this point a decision will be made whether to transplant a second islet dose with subsequent safety and efficacy follow up. Patients will then be further followed for one year.

“Sernova’s FDA clearance to commence human clinical trials in the United States is an exciting step forward in diabetes research, initially focused to reduce the risk of hypoglycemia unawareness, a complication in which a patient is unaware of a deep drop in blood sugar that can have life threatening consequences,” said Dave Prowten, President and CEO of JDRF Canada. “This is also an example of the international collaboration fostered by JDRF-funded projects to accelerate transformative research to benefit the T1D community,” added Mr. Prowten.

About Sernova’s Cell Pouch

The Cell Pouch is a novel, proprietary, scalable, implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and/or hormones as required to treat disease. The device is designed upon implantation to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells. The device with therapeutic cells has been shown to provide long term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin producing cells in humans.

About Diabetes

T1D is a life-threatening disease in which the body's immune system mistakenly attacks and kills the pancreatic cells that produce insulin—a hormone that is essential for life because of its role to help the body use glucose. The existing standard of care for patients with TID is suboptimal. To date, there is no cure for T1D, and people living with the disease are dependent on exogenous insulin therapy to help keep their blood-sugar levels from spiking too high, which can lead to long-term complications such as kidney and heart diseases or an acute, potentially deadly health crisis. Present-day insulin therapy is, however, an imperfect treatment method that requires people with T1D to carefully monitor their blood sugar throughout the day and take multiple, calculated doses of insulin based on food intake, exercise, stress, illness and other factors. A miscalculation or unexpected variable leading to high or low blood sugar episodes are daily threats, and only a third of people with T1D achieve their long-term blood glucose targets, placing them at risk for T1D-related health complications.

Conference Call Details

To participate in this live conference call, please dial + 1-877-858-5743 prior to the scheduled conference call time. International callers should dial +1-858-609-8959. The conference participant pass code is 355 040. Following the conference call a recording will be available at www.sernova.com

About Sernova Corp

Sernova Corp is developing disruptive regenerative medical technologies using a medical device and immune protected therapeutic cells to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested nearly $2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939 philip.toleikis@sernova.com www.sernova.com

Ray Matthews & Associates Tel: (604) 818-7778\ www.raymatthews.ca ray@raymatthews.ca

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made, which include our belief about the conduct and outcome of clinical trials and that Sernova will be able to raise additional capital to fund its clinical programs including its planned US FDA clinical trial. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

3Power Group PSPW in default and bancrupt for years see Court order to pay millions with interest
CRG Finance AG v. Prime Sun Power, Inc., No. 1:2012cv08258 - Document 11 (S.D.N.Y. 2013)
Court Description: OPINION & ORDER re: 5 MOTION to Compel Arbitration. On November 14, 2012, plaintiff CRG Finance AG ("CRG") filed a complaint against defendant Prime Sun Power ("PSP") to recover 470,OOO, plus interest, for breach of a promissor y note. PSP moved to compel arbitration and dismiss the complaint on January 17, 2013. For the reasons discussed below, PSP's motion is granted. For the foregoing reasons, the Court GRANTS PSP's motion to dismiss CRG's complaint and compel arbitration. The Clerk of Court is directed to enter judgment and closethis case. SO ORDERED. (Signed by Judge Paul A. Crotty on 5/23/2013) (rsh)

https://cases.justia.com/federal/district-courts/new-york/nysdce/1:2012cv08258/404018/11/0.pdf?ts=1411561536

AFRICA HYDROCARBONS PROVIDES UPDATE ON ITS PROPOSED CHANGE OF BUSINESS TO BECOME BLOCKCHAIN TECHNOLOGY COMPANY, WITH INITIAL FOCUS ON MINING CRYPTOCURRENCIES
New Name: BlockchainK2, Corp
New trading symbol: BITK
Raising $3m and Coming soon

BlockchainK2, Corp. ticker: BITK in Canada company changing business into tech
Africa Hydrocarbons to complete financing in 10 days



2018-01-05 18:17 ET - News Release


Mr. Douglas Wu reports

AFRICA HYDROCARBONS PROVIDES UPDATE ON ITS PROPOSED CHANGE OF BUSINESS TO BECOME BLOCKCHAIN TECHNOLOGY COMPANY, WITH INITIAL FOCUS ON MINING CRYPTOCURRENCIES

Africa Hydrocarbons Inc. has provided an update on its previously announced change-of-business transaction pursuant to the policies of the TSX Venture Exchange, with the result that the company will become a blockchain technology company, listed on the exchange (see the company's Nov. 23, 2017, press release).

Further to that previous announcement, upon completion of the COB transaction, the company now plans to acquire no less than $1.6-million worth of cryptocurrency mining rigs and other equipment necessary to commence operations and mine bitcoin (algorithm SHA256), subject to larger acquisitions of equipment, should the company raise a larger amount of funds in connection with the COB transaction. The company executed a non-binding agreement on Oct. 25, 2017, with a cryptocurrency mining equipment supplier in connection with such order, and expects that it should receive the equipment within two months of making such order, which order will be made upon completion of the COB transaction, unless the exchange grants early approval to the company to make such equipment order.

The company has also made the determination to build its initial cryptocurrency mining facility at a third party data centre, located in the state of Georgia in the United States, a low-cost electricity jurisdiction.

Financing

With respect to the company's previously announced non-brokered private placement of subscription receipts that is being completed concurrently with the COB transaction (see the company's Nov. 24, 2017, press release), the company has received incredible interest and expects to close such financing within the next seven to 10 days, if not sooner.

Annual general and special meeting of shareholders

The company is also pleased to announce that all resolutions presented at the annual general and special meeting of shareholders of the company on Jan. 4, 2018, were approved, including the resolution to change the name of the company to BlockchainK2 Corp. The company has reserved the stock symbol BITK in connection with such proposed name change. The name and stock symbol change will be completed in connection with the COB transaction and is subject to applicable exchange and other regulatory approvals.

Board of directors and management

As previously announced, current directors, Douglas Wu, Sergei Stetsenko and Andri Stytsenko, will remain on the board of directors upon completion of the COB transaction. Biographies for Mr. Wu and Mr. Stetsenko are set forth in the company's Nov. 23, 2017, press release. As for Mr. Stytsenko, he is a dual citizen of Canada and the Ukraine, and has a degree in petroleum engineering, with over 28 years in the industry, including six years at Halliburton in Western Canada. He is also an early adopter of cryptocurrency mining and has been involved with accessing suitable data centre locations with economic energy sources, both in Western Canada and Eastern Europe.

General

The COB transaction is conditional upon, among other things:

The company preparing a filing statement in accordance with the rules of the exchange, outlining the terms of the COB transaction and the resulting business of the company;
Receipt of all requisite regulatory approvals, including the approval of the exchange, and any third party approvals and authorizations (if applicable);
The company obtaining the requisite shareholder approvals for the COB transaction (as applicable);
The company completing a private placement financing for minimum gross proceeds of not less than $2-million;
The company meeting the applicable initial listing requirements of the exchange as a technology issuer (pursuant to Policy 2.1 (Initial Listing Requirements of the Exchange)), including, without limitation, the public float requirements.
Trading in the common shares of the company has been halted in accordance with the policies of the exchange and will remain halted until such time as all required documentation has been filed with and accepted by the exchange and permission to resume trading has been obtained from the exchange. The company will then operate within the technology sector. Since: (i) the common shares of the company are listed on the NEX market of the exchange, (ii) the proposed COB transaction does not constitute a related-party transaction under the policies of the exchange, (iii) the company is not, and does not expect to be, subject to a cease trade order upon completion of the COB transaction, and (iv) shareholder approval is not required to complete the COB transaction under applicable corporate and securities laws, the company does not expect to be required to seek shareholder approval for the COB transaction.

The company will continue to issue additional press releases related to the COB transaction, the private placement, sponsorship and other material information as it becomes available.

We seek Safe Harbor.

Kilo Gokd Zombie is coming back to life see recent acquisition of 10%+ KGL.V common shares news

Sergei Stetsenko Announces Purchase of Shares in Kilo Goldmines Ltd.


January 08, 2018 16:36 ET | Source: Sergei Stetsenko
TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Sergei Stetsenko (the “Purchaser”) announces his direct and indirect acquisition of shares of Kilo Goldmines Ltd., (“Kilo Goldmines” or the “Corporation”).

The Corporation’s head office is located at 141 Adelaide Street West, Suite 1200, Toronto, Ontario M5H 3L5. The common shares of the Corporation (the “Common Shares”) are listed on the TSX Venture Exchange under the symbol KGL.

Mr. Stetsenko is the Chief Executive Officer and beneficial owner of CRG Finance AG (“CRG Finance”), an investment company based out of Zug, Switzerland. Between December 28, 2017 and January 5, 2018, CRG Finance purchased, through market transactions on the TSX Venture Exchange, 3,737,000 Common Shares of the Corporation representing approximately 2.2% of the Corporation’s outstanding Common Shares. The Common Shares were purchased at an average price of $0.041 per Common Share for total proceeds of $153,425.00.

Prior to this sale, the Purchaser directly owned and controlled an aggregate of 10,043,000 Common Shares, while CRG Finance directly owned and controlled an aggregate of 3,025,000 Common Shares. In addition, the Purchaser owns and controls, directly or indirectly, an aggregate of 2,300,000 Common Share purchase warrants of the Corporation (each a “Warrant”), with an aggregate of 2,000,000 Warrants held directly and 300,000 Warrants held by CRG Finance. Each Warrant entitles the holder to purchase one additional Common Share at a price of $0.135 per Common Share. These holdings represented approximately 7.7% of the then issued and outstanding Common Shares on a non-diluted basis and 9.1% on a partially diluted basis assuming exercise of the Warrants.

Following this sale the Purchaser, directly, and through CRG Finance, owns and controls an aggregate of 16,805,000 common shares and 2,300,000 Warrants, representing approximately 9.9% of the outstanding common shares on a non-diluted basis and 11.3% on a partially diluted basis assuming exercise of the Warrants.

The Common Shares were purchased for investment purposes. The Purchaser has a long-term view of the investment and may acquire additional shares either on the open market or through private acquisitions or sell the shares either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors.

A copy of the early warning report with respect to the foregoing will appear with Kilo Goldmines’ profile on the System for Electronic Document Analysis and Retrieval at www.sedar.com and may also be obtained by contacting:

Sergei Stetsenko
Telephone: +41793183937
E-mail: s.serge@gmail.com

Related Articles
More articles issued by Sergei Stetsenko
More articles related to:
Stock Market News

Sernova closes $4.2-million private placement



2016-06-30 18:33 ET - News Release



Mr. Philip Toleikis reports

SERNOVA COMPLETES PRIVATE PLACEMENT OF $4,200,000

Sernova Corp. has completed a non-brokered private placement of $4.2-million, pursuant to which Sernova issued a total of 16.8 million units in two closings (June 27, 2016, and June 30, 2016).

Each unit issued in the private placement consists of one common share and one common share purchase warrant, and each warrant is exercisable into one share at a price of 35 cents per share for a 24-month exercise period, subject to abridgment of the exercise period (after the expiry of the four-month hold period) on 30 days notice to holders in the event that the 20-day volume-weighted price of the shares exceeds 50 cents.

The gross proceeds from the private placement will be used to finance a United States-based clinical trial ($2.5-million is allocated), and to finance Sernova's research and development programs, including corporate and academic collaborations ($1.2-million is allocated) using its platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes (approximately $500,000).

The company compensated finders by way of cash fees of $130,462.50 and 521,850 non-transferable finder warrants, each such finder warrant having the same terms as the unit warrants. Finders were Richardson GMP, Echelon Wealth Partners, Gravitas Securities Inc., Aventine Management Group, Raymond James, Mackie Research Capital Corp., Canaccord Genuity, CMF AG and CRF Finance AG.

All of the securities issued in connection with the private placement are subject to a four-month hold period from the date of issuance in accordance with applicable provincial securities laws in Canada. The company confirms that there is no material fact or material change about the company that has not been generally disclosed.

We seek Safe Harbor.

Sernova closes $4.2-million private placement



2016-06-30 18:33 ET - News Release



Mr. Philip Toleikis reports

SERNOVA COMPLETES PRIVATE PLACEMENT OF $4,200,000

Sernova Corp. has completed a non-brokered private placement of $4.2-million, pursuant to which Sernova issued a total of 16.8 million units in two closings (June 27, 2016, and June 30, 2016).

Each unit issued in the private placement consists of one common share and one common share purchase warrant, and each warrant is exercisable into one share at a price of 35 cents per share for a 24-month exercise period, subject to abridgment of the exercise period (after the expiry of the four-month hold period) on 30 days notice to holders in the event that the 20-day volume-weighted price of the shares exceeds 50 cents.

The gross proceeds from the private placement will be used to finance a United States-based clinical trial ($2.5-million is allocated), and to finance Sernova's research and development programs, including corporate and academic collaborations ($1.2-million is allocated) using its platform technology to treat diabetes and other serious disease conditions, as well as for general corporate purposes (approximately $500,000).

The company compensated finders by way of cash fees of $130,462.50 and 521,850 non-transferable finder warrants, each such finder warrant having the same terms as the unit warrants. Finders were Richardson GMP, Echelon Wealth Partners, Gravitas Securities Inc., Aventine Management Group, Raymond James, Mackie Research Capital Corp., Canaccord Genuity, CMF AG and CRF Finance AG.

All of the securities issued in connection with the private placement are subject to a four-month hold period from the date of issuance in accordance with applicable provincial securities laws in Canada. The company confirms that there is no material fact or material change about the company that has not been generally disclosed.

We seek Safe Harbor.

Sernova Corp is a clinical stage company, developing highly disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, and haemophilia A.

Sernova’s novel approach uses therapeutic cells placed into an implanted medical device to produce proteins or hormones which are in short supply or missing from the body due to the underlying disease state. The Cell Pouch System™, is an implantable, scalable medical device about the size of a business card which provides a natural “organ-like” environment for the long term survival and function of therapeutic cells such as insulin producing islets to treat diabetes. The Therapeutic Cells placed into the device may be natural (human) donor cells, or cells that can be a source to treat millions of patients including stem cell derived insulin responsive cells or xenogeneic cells. Sernova uses proprietary local immune protection technologies which protect therapeutic cells within the Cell Pouch™ from immune system attack reducing or eliminating the need for daily anti-rejection drugs. Sernova’s approach is designed to make future therapeutic cell replacement a simple outpatient procedure that can be performed in virtually any hospital setting. Using a medical device and therapeutic cell strategy to treat chronic diseases, Sernova is positioned for significant revenue upon commercialization of its “disruptive paradigm-shifting” platform technology.

Sernova’s team is focused on development of the Cell Pouch System™ for diabetes to treat both Type-1 and Type-2 patients who become insulin dependent – representing a treatable population of an estimated 50M patients worldwide currently taking insulin within Sernova’s patented countries. Sernova is also focused on development of the Cell Pouch System™ for the treatment of Hemophilia A through use of corrected patient’s cells placed in the Cell Pouch™ which is then expected to release Factor VIII at a constant rate.

TECHNOLOGY HIGHLIGHTS

The Standard of Care for patients with reduced or missing critical hormones or proteins such as insulin is often monitoring blood levels and injecting these proteins multiple times a day with a consequence of poor compliance and serious side effects resulting in over $150B/yr hospital costs for diabetes alone. Cell therapy is an alternative for patients with chronic diseases; however, there is no currently approved device to house and protect these cells in the body and no method to make the therapy a simple outpatient procedure. Instead, often cells are injected multiple times into blood vessels in an extremely expensive (>$100,000) and risky procedure, where many cells die through blood-derived inflammation and clotting, resulting in the need for repeat operations. Hence, the current standard of care for local cell therapy is limited by expensive procedures, poor cell survival and inappropriate delivery coupled with a lack of donors.
Sernova’s Cell Pouch System™ is a versatile, scalable implantable medical device made of materials approved for permanent use in the body, designed by biomedical engineers and biologists. Placed under the skin or in other locations, it develops organ-like characteristics (including vascularization) for survival and long term function of therapeutic cells. A natural environment where therapeutic cells are housed within a tissue matrix, rich in microvessels is expected to conserve cell number, and promote natural function - increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.
Sernova’s Therapeutic Cell technologies involve the use of natural donor cells, stem cell derived insulin responsive cells or xenogeneic cells to replace cells in the body that no longer produce the therapeutic proteins.
Sernova’s Local Immune Protection Technologies placed within the Cell Pouch™ with therapeutic cells is expected to eliminate the need for systemically administered toxic and expensive anti-rejection drugs ($10-15,000/yr).

FIRST THERAPEUTIC APPLICATION - DIABETES
The Cell Pouch™ has been contract manufactured in accordance with the strict guidelines of ISO13485, as mandated by the FDA. In preclinical safety and efficacy studies, the Cell Pouch™ with islets has been shown to be safe and to control sugar levels in small (isograft – similar cell transplants) and large animal transplantation models of diabetes including an autograft model (self-islets are placed into the Cell Pouch™) and an allograft model (donor islets are placed into the Cell Pouch™). Sernova’s technologies have been independently proven under collaboration at the University of Alberta in a marginal islet mass study showing that a small dose of islets can make diabetic animals insulin independent at the 100 day time point. Several of Sernova’s important preclinical studies have been funded in part by agencies such as the National Research Council (IRAP) of Canada. In addition to these studies, the Cell Pouch™ has been shown to be biocompatible in a series of FDA mandated preclinical studies (ISO10993).

Sernova Corp., received Health Canada Approval to conduct a Phase I/II human clinical trial assessing the safety and efficacy of Sernova's Cell Pouch™ with transplanted insulin-producing islets in patients with insulin-dependent diabetes. The primary endpoint of safety and biocompatibility has been demonstrated. Results have been presented at the International Pancreas and Islet Transplantation Association and at the 2015 American Diabetes Association Meeting. The Company is currently preparing for a U.S. clinical study of the Cell Pouch to assess efficacy in diabetes at a major transplantation center.

ADDITIONAL PRODUCT OPPORTUNITIES/PARTNERING/M&A
Sernova is also developing its local immune technologies to reduce or eliminate the need for antirejection regimens. Furthermore, with the success of the Cell Pouch™ to date, Sernova is developing technologies to provide an unlimited source of locally immune protected cells including stem cell derived insulin responsive cells and xenogeneic cells to treat the 50M patients currently taking insulin worldwide.

The Company is currently also developing a product for Haemophilia A as member of a European Consortium (HemAcure) which has recently received approximately 5.6M EU ($8.5M CAD) funding from the European Union with a successful, highly prestigious European Union Horizon 2020 grant. The grant is to develop the product for clinical trials in patients with Hemophilia A and is expected to reduce or eliminate the need for multiple weekly infusions of Factor VIII. The current market for Factor VIII which must be infused thrice weekly for prophylactic treatment is approximately $5.0B/yr. Sernova plans to develop other indications using the Cell Pouch System™ to treat diseases such as Thyroid disease, with approximately 250,000 patients/yr who could benefit from a cell therapy approach. The company is seeking corporate partners for these therapies and plans to in-license additional complementary technologies.

SERNOVA’S MANAGEMENT/BOARD/ADVISORY BOARD

Management Team: President and CEO since May 2009 – Dr. Philip Toleikis: Former VP Pharmacology R&D, Angiotech Pharmaceuticals, where he was part of the team that developed the multi-billion dollar drug-eluting stent and other drug-eluting medical devices; Chief Financial Officer, Ralph Deiterding: CPA, CA, CMA is a finance veteran with over 20 years of experience, primarily in senior finance roles at Toronto Stock Exchange listed software vendors; Senior Director R&D - Delfina Siroen: BSc. Hon. MSc. with over 20 years in managing academic and corporate R&D teams; Business Development – Nick Borrelly: 25 years corporate development (Ciba-Geigy, Novartis and Sanofi-Aventis).

Board of Directors: Chairman Frank Holler – CEO and partner BC Advantage Funds; Jeffery Bacha – CEO Delmar Pharmaceuticals, Inc.; Bruce Weber – V.P Clinical, Regulatory and QA Innovia LLC; James Parsons, CA; Dr. Philip Toleikis, President and CEO Sernova Corp.

As Servova approaches near-future catalysts, this clinical stage regenerative medicine company is poised to a become a ‘difference maker’ for millions of patients globally suffering from Diabetes and Hemophilia. For a quick cursory read, please clickhttp://www.sernova.com/pdf/Sernova%20Corp%20Fact%20Sheet%202015.pdf.

Sernova Corp is a clinical stage company, developing highly disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, and haemophilia A.

Sernova’s novel approach uses therapeutic cells placed into an implanted medical device to produce proteins or hormones which are in short supply or missing from the body due to the underlying disease state. The Cell Pouch System™, is an implantable, scalable medical device about the size of a business card which provides a natural “organ-like” environment for the long term survival and function of therapeutic cells such as insulin producing islets to treat diabetes. The Therapeutic Cells placed into the device may be natural (human) donor cells, or cells that can be a source to treat millions of patients including stem cell derived insulin responsive cells or xenogeneic cells. Sernova uses proprietary local immune protection technologies which protect therapeutic cells within the Cell Pouch™ from immune system attack reducing or eliminating the need for daily anti-rejection drugs. Sernova’s approach is designed to make future therapeutic cell replacement a simple outpatient procedure that can be performed in virtually any hospital setting. Using a medical device and therapeutic cell strategy to treat chronic diseases, Sernova is positioned for significant revenue upon commercialization of its “disruptive paradigm-shifting” platform technology.

Sernova’s team is focused on development of the Cell Pouch System™ for diabetes to treat both Type-1 and Type-2 patients who become insulin dependent – representing a treatable population of an estimated 50M patients worldwide currently taking insulin within Sernova’s patented countries. Sernova is also focused on development of the Cell Pouch System™ for the treatment of Hemophilia A through use of corrected patient’s cells placed in the Cell Pouch™ which is then expected to release Factor VIII at a constant rate.

TECHNOLOGY HIGHLIGHTS

The Standard of Care for patients with reduced or missing critical hormones or proteins such as insulin is often monitoring blood levels and injecting these proteins multiple times a day with a consequence of poor compliance and serious side effects resulting in over $150B/yr hospital costs for diabetes alone. Cell therapy is an alternative for patients with chronic diseases; however, there is no currently approved device to house and protect these cells in the body and no method to make the therapy a simple outpatient procedure. Instead, often cells are injected multiple times into blood vessels in an extremely expensive (>$100,000) and risky procedure, where many cells die through blood-derived inflammation and clotting, resulting in the need for repeat operations. Hence, the current standard of care for local cell therapy is limited by expensive procedures, poor cell survival and inappropriate delivery coupled with a lack of donors.
Sernova’s Cell Pouch System™ is a versatile, scalable implantable medical device made of materials approved for permanent use in the body, designed by biomedical engineers and biologists. Placed under the skin or in other locations, it develops organ-like characteristics (including vascularization) for survival and long term function of therapeutic cells. A natural environment where therapeutic cells are housed within a tissue matrix, rich in microvessels is expected to conserve cell number, and promote natural function - increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.
Sernova’s Therapeutic Cell technologies involve the use of natural donor cells, stem cell derived insulin responsive cells or xenogeneic cells to replace cells in the body that no longer produce the therapeutic proteins.
Sernova’s Local Immune Protection Technologies placed within the Cell Pouch™ with therapeutic cells is expected to eliminate the need for systemically administered toxic and expensive anti-rejection drugs ($10-15,000/yr).

FIRST THERAPEUTIC APPLICATION - DIABETES
The Cell Pouch™ has been contract manufactured in accordance with the strict guidelines of ISO13485, as mandated by the FDA. In preclinical safety and efficacy studies, the Cell Pouch™ with islets has been shown to be safe and to control sugar levels in small (isograft – similar cell transplants) and large animal transplantation models of diabetes including an autograft model (self-islets are placed into the Cell Pouch™) and an allograft model (donor islets are placed into the Cell Pouch™). Sernova’s technologies have been independently proven under collaboration at the University of Alberta in a marginal islet mass study showing that a small dose of islets can make diabetic animals insulin independent at the 100 day time point. Several of Sernova’s important preclinical studies have been funded in part by agencies such as the National Research Council (IRAP) of Canada. In addition to these studies, the Cell Pouch™ has been shown to be biocompatible in a series of FDA mandated preclinical studies (ISO10993).

Sernova Corp., received Health Canada Approval to conduct a Phase I/II human clinical trial assessing the safety and efficacy of Sernova's Cell Pouch™ with transplanted insulin-producing islets in patients with insulin-dependent diabetes. The primary endpoint of safety and biocompatibility has been demonstrated. Results have been presented at the International Pancreas and Islet Transplantation Association and at the 2015 American Diabetes Association Meeting. The Company is currently preparing for a U.S. clinical study of the Cell Pouch to assess efficacy in diabetes at a major transplantation center.

ADDITIONAL PRODUCT OPPORTUNITIES/PARTNERING/M&A
Sernova is also developing its local immune technologies to reduce or eliminate the need for antirejection regimens. Furthermore, with the success of the Cell Pouch™ to date, Sernova is developing technologies to provide an unlimited source of locally immune protected cells including stem cell derived insulin responsive cells and xenogeneic cells to treat the 50M patients currently taking insulin worldwide.

The Company is currently also developing a product for Haemophilia A as member of a European Consortium (HemAcure) which has recently received approximately 5.6M EU ($8.5M CAD) funding from the European Union with a successful, highly prestigious European Union Horizon 2020 grant. The grant is to develop the product for clinical trials in patients with Hemophilia A and is expected to reduce or eliminate the need for multiple weekly infusions of Factor VIII. The current market for Factor VIII which must be infused thrice weekly for prophylactic treatment is approximately $5.0B/yr. Sernova plans to develop other indications using the Cell Pouch System™ to treat diseases such as Thyroid disease, with approximately 250,000 patients/yr who could benefit from a cell therapy approach. The company is seeking corporate partners for these therapies and plans to in-license additional complementary technologies.

SERNOVA’S MANAGEMENT/BOARD/ADVISORY BOARD

Management Team: President and CEO since May 2009 – Dr. Philip Toleikis: Former VP Pharmacology R&D, Angiotech Pharmaceuticals, where he was part of the team that developed the multi-billion dollar drug-eluting stent and other drug-eluting medical devices; Chief Financial Officer, Ralph Deiterding: CPA, CA, CMA is a finance veteran with over 20 years of experience, primarily in senior finance roles at Toronto Stock Exchange listed software vendors; Senior Director R&D - Delfina Siroen: BSc. Hon. MSc. with over 20 years in managing academic and corporate R&D teams; Business Development – Nick Borrelly: 25 years corporate development (Ciba-Geigy, Novartis and Sanofi-Aventis).

Board of Directors: Chairman Frank Holler – CEO and partner BC Advantage Funds; Jeffery Bacha – CEO Delmar Pharmaceuticals, Inc.; Bruce Weber – V.P Clinical, Regulatory and QA Innovia LLC; James Parsons, CA; Dr. Philip Toleikis, President and CEO Sernova Corp.

As Servova approaches near-future catalysts, this clinical stage regenerative medicine company is poised to a become a ‘difference maker’ for millions of patients globally suffering from Diabetes and Hemophilia. For a quick cursory read, please clickhttp://www.sernova.com/pdf/Sernova%20Corp%20Fact%20Sheet%202015.pdf.

Sernova Corp is a clinical stage company, developing highly disruptive platform technologies to treat chronic diseases through a regenerative medicine approach. Sernova’s primary focus is in developing technologies for the treatment of patients with insulin-dependent (TI) diabetes, and haemophilia A.

Sernova’s novel approach uses therapeutic cells placed into an implanted medical device to produce proteins or hormones which are in short supply or missing from the body due to the underlying disease state. The Cell Pouch System™, is an implantable, scalable medical device about the size of a business card which provides a natural “organ-like” environment for the long term survival and function of therapeutic cells such as insulin producing islets to treat diabetes. The Therapeutic Cells placed into the device may be natural (human) donor cells, or cells that can be a source to treat millions of patients including stem cell derived insulin responsive cells or xenogeneic cells. Sernova uses proprietary local immune protection technologies which protect therapeutic cells within the Cell Pouch™ from immune system attack reducing or eliminating the need for daily anti-rejection drugs. Sernova’s approach is designed to make future therapeutic cell replacement a simple outpatient procedure that can be performed in virtually any hospital setting. Using a medical device and therapeutic cell strategy to treat chronic diseases, Sernova is positioned for significant revenue upon commercialization of its “disruptive paradigm-shifting” platform technology.

Sernova’s team is focused on development of the Cell Pouch System™ for diabetes to treat both Type-1 and Type-2 patients who become insulin dependent – representing a treatable population of an estimated 50M patients worldwide currently taking insulin within Sernova’s patented countries. Sernova is also focused on development of the Cell Pouch System™ for the treatment of Hemophilia A through use of corrected patient’s cells placed in the Cell Pouch™ which is then expected to release Factor VIII at a constant rate.

TECHNOLOGY HIGHLIGHTS

The Standard of Care for patients with reduced or missing critical hormones or proteins such as insulin is often monitoring blood levels and injecting these proteins multiple times a day with a consequence of poor compliance and serious side effects resulting in over $150B/yr hospital costs for diabetes alone. Cell therapy is an alternative for patients with chronic diseases; however, there is no currently approved device to house and protect these cells in the body and no method to make the therapy a simple outpatient procedure. Instead, often cells are injected multiple times into blood vessels in an extremely expensive (>$100,000) and risky procedure, where many cells die through blood-derived inflammation and clotting, resulting in the need for repeat operations. Hence, the current standard of care for local cell therapy is limited by expensive procedures, poor cell survival and inappropriate delivery coupled with a lack of donors.
Sernova’s Cell Pouch System™ is a versatile, scalable implantable medical device made of materials approved for permanent use in the body, designed by biomedical engineers and biologists. Placed under the skin or in other locations, it develops organ-like characteristics (including vascularization) for survival and long term function of therapeutic cells. A natural environment where therapeutic cells are housed within a tissue matrix, rich in microvessels is expected to conserve cell number, and promote natural function - increasing cell survival, while significantly increasing the number of treatable patients beyond those with severe disease.
Sernova’s Therapeutic Cell technologies involve the use of natural donor cells, stem cell derived insulin responsive cells or xenogeneic cells to replace cells in the body that no longer produce the therapeutic proteins.
Sernova’s Local Immune Protection Technologies placed within the Cell Pouch™ with therapeutic cells is expected to eliminate the need for systemically administered toxic and expensive anti-rejection drugs ($10-15,000/yr).

FIRST THERAPEUTIC APPLICATION - DIABETES
The Cell Pouch™ has been contract manufactured in accordance with the strict guidelines of ISO13485, as mandated by the FDA. In preclinical safety and efficacy studies, the Cell Pouch™ with islets has been shown to be safe and to control sugar levels in small (isograft – similar cell transplants) and large animal transplantation models of diabetes including an autograft model (self-islets are placed into the Cell Pouch™) and an allograft model (donor islets are placed into the Cell Pouch™). Sernova’s technologies have been independently proven under collaboration at the University of Alberta in a marginal islet mass study showing that a small dose of islets can make diabetic animals insulin independent at the 100 day time point. Several of Sernova’s important preclinical studies have been funded in part by agencies such as the National Research Council (IRAP) of Canada. In addition to these studies, the Cell Pouch™ has been shown to be biocompatible in a series of FDA mandated preclinical studies (ISO10993).

Sernova Corp., received Health Canada Approval to conduct a Phase I/II human clinical trial assessing the safety and efficacy of Sernova's Cell Pouch™ with transplanted insulin-producing islets in patients with insulin-dependent diabetes. The primary endpoint of safety and biocompatibility has been demonstrated. Results have been presented at the International Pancreas and Islet Transplantation Association and at the 2015 American Diabetes Association Meeting. The Company is currently preparing for a U.S. clinical study of the Cell Pouch to assess efficacy in diabetes at a major transplantation center.

ADDITIONAL PRODUCT OPPORTUNITIES/PARTNERING/M&A
Sernova is also developing its local immune technologies to reduce or eliminate the need for antirejection regimens. Furthermore, with the success of the Cell Pouch™ to date, Sernova is developing technologies to provide an unlimited source of locally immune protected cells including stem cell derived insulin responsive cells and xenogeneic cells to treat the 50M patients currently taking insulin worldwide.

The Company is currently also developing a product for Haemophilia A as member of a European Consortium (HemAcure) which has recently received approximately 5.6M EU ($8.5M CAD) funding from the European Union with a successful, highly prestigious European Union Horizon 2020 grant. The grant is to develop the product for clinical trials in patients with Hemophilia A and is expected to reduce or eliminate the need for multiple weekly infusions of Factor VIII. The current market for Factor VIII which must be infused thrice weekly for prophylactic treatment is approximately $5.0B/yr. Sernova plans to develop other indications using the Cell Pouch System™ to treat diseases such as Thyroid disease, with approximately 250,000 patients/yr who could benefit from a cell therapy approach. The company is seeking corporate partners for these therapies and plans to in-license additional complementary technologies.

SERNOVA’S MANAGEMENT/BOARD/ADVISORY BOARD

Management Team: President and CEO since May 2009 – Dr. Philip Toleikis: Former VP Pharmacology R&D, Angiotech Pharmaceuticals, where he was part of the team that developed the multi-billion dollar drug-eluting stent and other drug-eluting medical devices; Chief Financial Officer, Ralph Deiterding: CPA, CA, CMA is a finance veteran with over 20 years of experience, primarily in senior finance roles at Toronto Stock Exchange listed software vendors; Senior Director R&D - Delfina Siroen: BSc. Hon. MSc. with over 20 years in managing academic and corporate R&D teams; Business Development – Nick Borrelly: 25 years corporate development (Ciba-Geigy, Novartis and Sanofi-Aventis).

Board of Directors: Chairman Frank Holler – CEO and partner BC Advantage Funds; Jeffery Bacha – CEO Delmar Pharmaceuticals, Inc.; Bruce Weber – V.P Clinical, Regulatory and QA Innovia LLC; James Parsons, CA; Dr. Philip Toleikis, President and CEO Sernova Corp.

As Servova approaches near-future catalysts, this clinical stage regenerative medicine company is poised to a become a ‘difference maker’ for millions of patients globally suffering from Diabetes and Hemophilia. For a quick cursory read, please clickhttp://www.sernova.com/pdf/Sernova%20Corp%20Fact%20Sheet%202015.pdf.

SeeThruEquity Initiates Coverage on Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76

.

Accesswire

October 5, 2015 9:00 AM








?
?
?
?

. ?
?
?
.





..
.
.

NEW YORK, NY / ACCESSWIRE / October 5, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it recently initiated coverage of Sernova Corp. (TSX: SVA, OTCQB: SEOVF) with a Price Target of CAD $0.76.

The report is available here: SVA Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

With headquarters in London, Ontario, Sernova is a clinical stage medical company focused on developing disruptive platform technologies that use regenerative medicine to treat chronic diseases. Initially Sernova is developing medical technologies aimed at treating chronic metabolic diseases including Type 1 and Type 2 diabetes, blood disorders such as hemophilia, thyroid disease, and other diseases. We see several potential catalysts ahead for the company as it pursues a partner-based strategy for advancing its clinical development program - and ultimately commercialization – for the treatment of the approximately 30mn people worldwide who suffer from insulin-dependent diabetes.

"The company's patented Cell Pouch System(TM) is a novel, implantable medical device technology for delivering therapeutic cells in a safe and biologically appropriate environment," stated Ajay Tandon, CEO of SeeThruEquity. "We find the technology to be compelling, especially in light of the large market opportunity as 30 million people worldwide suffer from insulin-dependent diabetes. We are initiating coverage with a 12-month price target of CAD$0.76 per share."

Additional highlights from the report are as follows:

Cell Pouch System(TM) offers a novel approach to diabetes treatment

Sernova's Cell Pouch System(TM) is a subcutaneous implantable medical device technology that is designed for the transplantation of therapeutic cells, including donor, xenogeneic, or stem cell derived therapeutic cells to treat chronic diseases. The Cell Pouch System(TM) was custom designed to provide a natural environment for therapeutic cells, which then can produce missing proteins or hormones and release these therapeutics into the bloodstream. The Cell Pouch System™ can also provide local immune protection for the therapeutic cells and includes the full complement of technologies required to develop advanced cell-based treatments with applications in a number of chronic diseases involving the need for a missing protein, hormone or factor – suggesting that the technology has the potential for numerous indications beyond those enumerated by the company. Over the last six years Sernova has made considerable progress on its Cell Pouch System(TM) development program for insulin-dependent diabetes patients, with strong preclinical confirmation of safety and efficacy - as well as clinical success with human islets in brittle diabetics. Sernova recently secured access to a near-infinite supply of cells sourced from its licensed technology with University Health Network (UHN) of Toronto. We next expect the company to move forward to initiate a Phase 2 human trial using the Cell Pouch System(TM) to transplant therapeutic cells to insulin dependent diabetes patients.

Large market for diabetes therapeutics

Initially Sernova is targeting diabetes - a chronic disease that occurs when the pancreas does not produce enough insulin. Diabetes is a widespread and growing disease that affects approximately 387mn across the globe, a figure that is expected to rise to 592mn by 2035, according to the International Diabetes Federation (IDF). The cost of treating diabetes and its side effects represents a massive economic burden on healthcare, having been estimated at over $245Bn in North America alone. The initial target market for Sernova's Cell Pouch System(TM) is the 30mn insulin-dependent Type 1 and Type 2 diabetics worldwide. Although smaller in number, insulin dependent diabetics represent approximately 50% of the multi-billion dollar global market for diabetes. Following diabetes, Sernova's second clinical program for the Cell Pouch System(TM) is hemophilia, and the company also sees potential for the Cell Pouch System(TM) for treatment of thyroid disease, and other chronic diseases.

Initiate coverage with a price target of CAD $0.76

Our analysis indicates a fair value estimate of CAD $0.76 per share for Sernova. If achieved, the target represents potential upside of 145.2% from the recent price of CAD $0.31. We see Sernova as an intriguing speculative story in the healthcare sector with a potentially disruptive platform technology that is initially addressing the $420Bn+ global market for diabetes treatment, with several additional indications planned for the future.

Please review important disclosures on our website at www.seethruequity.com.

About Sernova Corp.

Sernova Corp. is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

Slapping the ask with 100 shares to increase market valuation of whole company by $15M is classic manipulation tactic and called "pain job" The commissions alone will cost you more then value - the true intent is to lie steal and deceive.

More exposure of PSPW microcap fraud coming soon

PSPW Audit smells fishy as published numbers do not reflect or account for accrued interest. as of April 10th 2016 - $1,986,000 in accrued DEBT is not reflected under current audit and SEC accounting division was alerted to this fact. PSPW will soon restate its audit - will not be surprised if they stop auditing books just to cover up prior deceptions.

PSPW Stock trading is nothing but paint job with 50% Mongolian P.... wide spread. Investor who got enticed into slapping the ask will loose 50% immediately in case he wants to sell. This is one way street into promoters pocket who manipulates PSPW all day long.

PSPW market capitalisation is $30M for what? Management Team delivered or created $0 Value. Assets = $0 DEBT!? Makes no sense.

PSPW appears to be nothing but a FRONT for some shady dealing and I will not be surprised if Money Laundering reasons involved here.

Investigate before you Invest!

All your PSPW charts with allotments will not work or apply to PSPW 3Power Energy Group, as PSPW indicates less then $3000 in cash assets on its balance sheet. Assets = $0. Management Credibility = $0 Value created in last 7 years = $0. PSPW stock being propped up and manipulated by painting the tape. ie: "slap the ask" done by group of offshore promoters and hired story writers.. Exactly the type of thing SEC has been cracking down recently. Read before you donate your hard earned cash to group of mysterious milk shakes:
https://www.sec.gov/News/PressRelease/Detail/PressRelease/1370540714936

disclosure: I have no position in the pspw stock.

Yes. Be informed Complaint was filed with US Regulator for incorrect accounting and fraud involved at 3Power Group.

3 Power Energy Group, Inc PINK SHEET QUOTED SYMBOL PSPW will have all or any assets seized by US Marshals as they are in Violation of Court Order Judgement in the amount of $1,986,282 as of April 10th 2016. Under Judgement 15% being accrued as long as company exists. Its only a matter of time before creditor will seize all or any assets of PSPW in Dubai or anywhere in the World unless they plan to change Jurisdiction to Somalia or Zimbabwe Stock Exchange. PSPW or 3POWER GROUP IS NOTHING BUT INVESTOR FRAUD and here are the reasons: : 1. PSPW has no assets. 2. PSPW has no business other then Monthly Newsletter issued to shareholders posted on website. 3. Not one single announced contract generated revenues or closed since inception. Stock was promoted on heavy volume to sponsored lists of investors including I-HUB list. 4. Contracts with 3Power are fake: read earlier research done by others on RUDANA(name similar to ROTANA HOLDINGS) goal to defraud investors: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=59319637
same Group involved in FOUR pump and dump: http://www.citronresearch.com/4c-controls-otcfour-who-is-going-to-get-them-first-irs-department-of-homeland-security-or-the-sec/


3Power Energy Group Inc. PSPW was sued for defaulting on Loan obligations. Annual interest is 15% compounded daily at rate of $827 per day. Company owes $1,986,282.

http://law.justia.com/cases/federal/district-courts/new-york/nysdce/1:2012cv08258/404018/11/

The financial disclosure done by 3Power Energy Group is incorrect and Q should be refilled as it does not indicate total correct loan and interest amount outstanding. See below from latest fillings.

Item 1. Legal Proceedings

On November 14, 2012, CRG Finance AG (“CRG”) filed a complaint in the District Court for Southern District of New York for allegedly beaching a promissory note (See Note 5 above).



The Final Hearing in the AAA arbitration took place on February 27, 2014, wherein the Company was not able to establish its defense due to the lack of evidence from Rudana. The AAA Arbitrator entered an award of Euro 470,000 plus interest at the annual rate of 7.5% against the Company. As of March 31, 2014, the total award against the Company is Euro 728,241 ($816,795). On or about April 4, 2014, in an effort to perfect this award against the Company, CRG filed a petition with the Southern District of New York seeking to confirm the award. In addition, the Company accrued total of $56,835 as reimbursement of attorney fees and cost incurred by CRG and $15,500 as administrative fees and compensation to the Arbitrator.

On July 8, 2014, a judgment has been entered against 3Power in the Southern District of New York in the amount of $1,086,186. That judgment remains unpaid.

Loosing close to $1,000 per day in accruing interest payments hurts the widows and orphans who invested into PSPW stock pump not knowing true disclosure or not being properly informed of the risks involved here.. you cannot deny the fact that 3Power defaulted and no one other then insiders will provide funding to PSPW. Would you WAKL loan more money to someone if they have not paid you back? be aware - creditor can close this shop down any day!

You can hide real facts with nonsense posts only for so long.. The fact is company is broke and management with key promoters gaining at the expense of new unsuspecting shareholders. The clock is ticking before regulators take notice of poor risk disclosure and potential manipulation involved at 3Power

Kilo Goldmines Ltd. common stock is up 200% since my last posting. Undiscovered sleeper stock with $4 per ounce for proven gold reserves compared to gold mining industry of $30 per ounce. Buy and Hold KGL! Happy Investing to all Longs!

Sernova SVA.V Sketches of Progress - How Disruptive Technologies Reshape our World. Billion Dollar opportunity for 0.25c per share.


March 29, 2016 12:45 PM

PRINCE GEORGE, BC / ACCESSWIRE / March 29, 2016 / Disruptive innovations have the potential to truly reshape the world in which we live and work.

Regenerative medicine means replacing, engineering or regenerating human cells, tissues or organs with the goal being to re-establish normality for conditions that currently are beyond repair.

An example of a highly disruptive technology is regenerative medicine where living therapeutic cells placed within an implanted medical device manufacture and release required medicines into the body as needed.

For diabetes, this technology has the potential to disrupt the entire multibillion insulin and insulin pump market as the therapeutic cells can read blood sugar levels and manufacture and release all the hormones required to appropriately control blood sugar. The same can occur in other therapeutic areas such as hemophilia where Factor VIII can be produced by therapeutic cells within an implanted device rather than being infused multiple times weekly.

Sernova Corp. (TSX.V: SVA; OTCQB: SEOVF) has a technology platform with the potential to do multiple deals based on disease indication, cell type and/or device technology. A potential licensee Company, depending on their needs, might require Sernova's Cell Pouch™ technology, Stem Cell-Derived Therapeutic cells or Sernova's developing technology which protects the therapeutic cells inside their Cell Pouch™ from the body's immune system. They may be focused on a single clinical indication such as diabetes or more than one. Deals could be done regionally or globally depending on the need.

There are many companies operating in the regenerative medicine space whose products have the potential to be disrupted and each is a potential suitor for one, or more, of Sernova's technologies.

For the complete report on Aheadoftheherd.com: http://aheadoftheherd.com/Newsletter/2016/Sketches-Of-Progress.html.

About the author: Richard (Rick) Mills, Editor of www.Aheadoftheherd.com

Richard invests in the resource and biotechnology/pharmaceutical sectors and is the owner of http:www.Aheadoftheherd.com. His articles have been published on over 400 websites, including:

WallStreetJournal, USAToday, NationalPost, Lewrockwell, MontrealGazette, VancouverSun, CBSnews, HuffingtonPost, Beforeitsnews, Londonthenews, Wealthwire, CalgaryHerald, Forbes, Dallasnews, SGTreport, Vantagewire, Indiatimes, Ninemsn, Ibtimes, Businessweek, HongKongHerald, Moneytalks, SeekingAlpha, BusinessInsider, Investing.com, MSN.com and the Association of Mining Analysts. For more information about his newsletter, log on to: http:www.Aheadoftheherd.com.

Media contact:

Jackie Rodriguez
646-430-5783

SOURCE: Aheadoftheherd.com

3Power Energy Group Inc. ordered to pay and indebted to CRG Finance AG. $1,986,282 as of April 10th 2016. Buyer be aware! Company is technically bankrupt and creditor can close it down. 3 Power has declared few thousand in assets on its balance sheet. $30M market capitalisation for company with no assets and huge debt is not innocent in nature. Investors be aware of potential manipulation of thinly traded stock controlled by one group of offshore promoters and high risk of stock fraud involved. Shareholders can alert SEC at: https://denebleo.sec.gov/TCRExternal/index.xhtml

3Power Energy Group Inc. PSPW was sued for defaulting on Loan obligations. Annual interest is 15% compounded daily at rate of $827 per day. Company owes $1,986,282.

http://law.justia.com/cases/federal/district-courts/new-york/nysdce/1:2012cv08258/404018/11/

The financial disclosure done by 3Power Energy Group is incorrect and Q should be refilled as it does not indicate total correct loan and interest amount outstanding. See below from latest fillings.

Item 1. Legal Proceedings



On November 14, 2012, CRG Finance AG (“CRG”) filed a complaint in the District Court for Southern District of New York for allegedly beaching a promissory note (See Note 5 above).



On January 17, 2013, the Company filed a motion to compel arbitration and on May 23, 2013, the Court granted the Company’s Motion to Compel and ordered that CRG file its claims as an AAA arbitration.



The Final Hearing in the AAA arbitration took place on February 27, 2014, wherein the Company was not able to establish its defense due to the lack of evidence from Rudana. The AAA Arbitrator entered an award of Euro 470,000 plus interest at the annual rate of 7.5% against the Company. As of March 31, 2014, the total award against the Company is Euro 728,241 ($816,795). On or about April 4, 2014, in an effort to perfect this award against the Company, CRG filed a petition with the Southern District of New York seeking to confirm the award. In addition, the Company accrued total of $56,835 as reimbursement of attorney fees and cost incurred by CRG and $15,500 as administrative fees and compensation to the Arbitrator.



On July 8, 2014, a judgment has been entered against 3Power in the Southern District of New York in the amount of $1,086,186. That judgment remains unpaid.

PSPW daily trading volume under $1 per day. Tape doesn't lie - treasury is broke and shareholders bought into default and soon defunct pink sheet shares. Hard to find greater fool here.. Ah??

The clock is ticking for PSPW delisting as the company is losing $530 in daily interest on unpaid loan. You are holding liability and not the asset via PSPW shares at 0.03c. This is major RED flag here. I hold gold and you have trash.

3 Power Energy Group, Inc. (PSPW) ordered to pay $1,081,586 to CRG Finance AG as Final Award in AAA Arbitration in New York, United States of America. Read the fine print:
http://www.scribd.com/doc/215888558/3-Power-Energy-Group-Inc-PSPW-ordered-to-pay-1-081-586-to-CRG-Finance-AG-as-Final-Award-in-AAA-Arbitration-in-New-York-United-States-of-America#scribd